相关实验视频

Updated: Jun 23, 2025

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Mechanism of Kemeng Fang's Inhibition of Podocyte Apoptosis in Rats with Membranous Nephropathy through the PI3K/AKT Signaling Pathway

Published on: August 23, 2024

在一次性膜性病中,关于免疫抑制的十个建议

Hernando Trujillo¹, Fernando Caravaca-Fontán^1,2, Manuel Praga³

¹Department of Nephrology, Hospital Universitario, 12 de Octubre, Madrid, Spain.

Clinical kidney journal

|June 25, 2024

概括

管理膜性病 (MN) 需要仔细考虑免疫抑制治疗 (IST). 本指南为最佳的患者护理提供了10个关键提示,重点关注风险分层和个性化监测,以改善结果.

科学领域:

腎臟病學 (nephrology) 是一種醫學專業.
免疫学免疫学免疫学
内部医学内部医学

背景情况:

膜性病 (MN) 管理在治疗选择和疾病监测方面存在重大挑战.
优化免疫抑制疗法 (IST) 和预防并发症对于患者的结果至关重要.

研究的目的:

为管理原发性膜性病 (MN) 提供10个基于证据的临床建议.
引导临床医生选择适当的免疫抑制疗法 (IST) 并监测疾病进展.
为了提高患者的治疗结果,并最大限度地减少与MN相关的并发症.

主要方法:

审查目前的证据和临床经验在初级MN管理.
制定10个关键建议,用于IST选择,监测和预防并发症.
考虑风险分层,治疗耐药性,复发和移植后复发.

主要成果:

建议包括在非脏病患者中避免IST,在持续性脏病综合征或功能下降的情况下启动IST.
具体的IST建议:中等风险患者使用rituximab (RTX) 或RTX加上氨酸抑制剂,高风险患者使用cyclophosphamide.
不鼓励初始使用葡萄糖皮质激素单疗法或mycophenolate mofetil;强调预防感染和个性化监测 (功能,蛋白尿,白蛋白,抗PLA2R水平).

结论:

为管理初级MN提供了一个全面的框架,包括对抗性疾病和复发的策略.
强调根据个体风险概况进行量身定制的监测和治疗调整的重要性.
解决了移植后MN复发的管理,提供监测和治疗指导.

关键词:

对抗PLA2R的抗体.环酸胺的使用方法免疫抑制疗法是一种免疫抑制疗法.膜性脏病是一种脏病.这就是Rituximab.

更多相关视频

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform

Digital Home-Monitoring of Patients after Kidney Transplantation: The MACCS Platform

Published on: April 12, 2021

相关概念视频

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...

Cell-mediated Immune Responses

Cell-mediated Immune Responses

Pulmonary Tuberculosis I

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...

Inflammatory Bowel Disease IV: Pharmacological Management

Inflammatory Bowel Disease IV: Pharmacological Management

Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...